Symbiotec Pharmalab IPO has achieved strong oversubscription of 8.2 times on its final day of bidding, with the issue receiving bids for 7.37 crore shares as against 1.31 crore shares on offer as of 10:40 AM on August 27, 2026, according to latest NSE data. The issue received bids for 1,05 crore shares as against 1,31 crore shares on offer, demonstrating robust investor interest. The retail investor portion was subscribed 6.11 times while the NII category led with 23.20 times subscription, representing significant improvement from the 0.06 times subscription recorded on the first day. The employee reservation portion maintained strong demand with 6.87 times subscription, while the QIB segment showed 0.61 times subscription, with Foreign Institutional Investors accounting for 2,90,685 of the 13,18,410 QIB bids received. The IPO officially opened for subscription on August 24, 2026, with a ₹1,757 crore issue size priced in the ₹938-₹988 per share band and bidding scheduled until August 27, 2026. As per NDTV Profit, allotment is expected to be finalised on August 28, 2026, with shares set to list on both BSE and NSE with a tentative listing date of September 1, 2026.
According to grey market trends, Symbiotec Pharmalab IPO maintains strong premium indicators with a grey market premium (GMP) of ₹285, indicating an estimated listing price of ₹1,273 per share, which is 28.85% higher than the IPO price of ₹988. As per NDTV Profit, the GMP currently stands at around ₹285 per share, with the pharma and biotech company having raised ₹526.2 crore from anchor investors, including major institutional players such as Citigroup Global Markets, BNP Paribas, Singularity AMC, Susquehanna Pacific and TIMF Holdings. The ₹1,757 crore issue is positioned as a premium offering in the pharmaceutical and biotechnology space, with the IPO price band translating to 469 times the face value at the floor price and 494 times at the cap price. However, investors should note that GMP is an unofficial market indicator and can fluctuate before the stock makes its debut.
The retail portion achieved 6.11 times subscription against 65.44 lakh shares reserved for the segment, demonstrating exceptional retail investor interest. As per NDTV Profit, the NII category led with 23.20 times subscription against 28.04 lakh shares on offer, while the QIB portion remained below full subscription at 0.61 times against 37.39 lakh shares reserved. The issue structure includes a fresh issue of ₹150 crore and an offer for sale (OFS) of ₹1,607 crore, with promoter Satwani Holdings and selling shareholders Rosewood Investments and India Business Excellence Fund III offering shares through the OFS. The minimum investment stands at ₹14,820 at the upper price band, with investors required to bid for a minimum of 15 shares. The company plans to list on both BSE and NSE with a tentative listing date of September 1, 2026, while IPO allotment is expected to be finalised on August 28, 2026.
Symbiotec Pharmalab has demonstrated robust financial growth with profit rising at a compound annual growth rate (CAGR) of 4.81% between FY24 and FY26 to ₹109.9 crore in FY26, while revenue increased at a CAGR of 10.16% during the same period to ₹869.15 crore. The company raised ₹526.2 crore through its anchor book, allotting 53.25 lakh equity shares to 34 anchor investors at ₹988 apiece. Notable anchor investors included eleven domestic mutual funds through 19 schemes, acquiring 31.98 lakh shares from funds managed by ICICI Prudential AMC, HDFC Mutual Fund, Motilal Oswal AMC, Mirae Asset, Tata Mutual Fund, Edelweiss, Groww Mutual Fund and ITI Mutual Fund. Insurance companies Tata AIA Life, Bajaj Life and Bharti AXA Life also participated, acquiring 4.25 lakh shares worth around ₹42 crore. As of March 31, 2026, the company had debt of around ₹380 crore, which is expected to decline to about ₹230 crore following the IPO. JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India) are the book-running lead managers to the issue. Of the fresh issue proceeds, ₹112.5 crore is proposed to be used towards debt repayment, while the remaining amount will be utilised for general corporate purposes.
Symbiotec Pharmalab has established itself as a dominant player in the global steroidal hormone API market, holding 38.2% global volume market share in corticosteroid APIs and 23.8% in steroidal-hormone APIs in FY26. As per Business Standard, the company is the only Indian and global player present across the top 10 APIs in both segments, with its portfolio of 60+ APIs catering to critical therapeutic areas including respiratory, dermatology, oncology and gynaecology. The research and development-driven, science-based pharmaceutical and biotechnology company operates as both an API manufacturer and contract development and manufacturing organisation (CDMO), while expanding into complex injectables. With over 30 years of industry experience, the company has evolved from a lab-scale steroidal-hormone API manufacturer into an industrial-scale, backward-integrated platform, following a backward-integrated farm/microbe-to-pharmacy model with in-house manufacturing of key starting materials for over 80% of its products by revenue. The company is also expanding into biologics, GLP-1, insulin, niche APIs and complex injectables, supported by its R&D and manufacturing capabilities. As of March 2026, the company had two operational industrial-scale API manufacturing facilities, with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres, while it has commissioned two additional manufacturing facilities at Ujjain and Mhow in Madhya Pradesh and is expanding its biologics manufacturing capacity with a proposed dedicated 14 KL fermentation facility at Ujjain.
